Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (INM)

Inmed Pharmaceuticals Inc (INM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,654
  • Shares Outstanding, K 6,057
  • Annual Sales, $ 4,140 K
  • Annual Income, $ -7,950 K
  • 60-Month Beta 0.10
  • Price/Sales 0.41
  • Price/Cash Flow N/A
  • Price/Book 0.13
Trade INM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.55
  • Most Recent Earnings $-0.19 on 02/13/24
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2620 +15.65%
on 04/17/24
0.4555 -33.48%
on 04/04/24
-0.0768 (-20.22%)
since 03/22/24
3-Month
0.2620 +15.65%
on 04/17/24
0.4718 -35.78%
on 03/07/24
-0.0750 (-19.84%)
since 01/24/24
52-Week
0.2620 +15.65%
on 04/17/24
2.0800 -85.43%
on 10/24/23
-0.8870 (-74.54%)
since 04/24/23

Most Recent Stories

More News
InMed (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD,...

INM : 0.3030 (+10.99%)
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization...

INM : 0.3030 (+10.99%)
InMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical...

AMD : 151.74 (-0.35%)
INM : 0.3030 (+10.99%)
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease...

INM : 0.3030 (+10.99%)
InMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting additional preclinical data...

INM : 0.3030 (+10.99%)
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal...

INM : 0.3030 (+10.99%)
InMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, has been granted an additional 180 days to...

INM : 0.3030 (+10.99%)
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of...

INM : 0.3030 (+10.99%)
InMed Pharmaceuticals (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for...

INM : 0.3030 (+10.99%)
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica subsidiaryVancouver,...

INM : 0.3030 (+10.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.

See More

Key Turning Points

3rd Resistance Point 0.4037
2nd Resistance Point 0.3703
1st Resistance Point 0.3367
Last Price 0.3030
1st Support Level 0.2697
2nd Support Level 0.2363
3rd Support Level 0.2027

See More

52-Week High 2.0800
Fibonacci 61.8% 1.3855
Fibonacci 50% 1.1710
Fibonacci 38.2% 0.9565
Last Price 0.3030
52-Week Low 0.2620

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar